This activity expired on May 27, 2024; credit is no longer available.

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

Media: Enduring Material
Activity Release Date: April 28, 2023
Activity Expiration Date: May 27, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC
• Collaborate with the interprofessional team to safely and effectively integrate ICI-based regimens into individualized treatment plans for eligible patients with advanced- and early-stage NSCLC
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers about ICI-based treatment options, importance of being vigilant about irAEs, and how to overcome challenges and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale School of Nursing
Oncology Nurse Practitioner
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Matthew A. Gubens, MD, MS
Associate Clinical Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Matthew A. Gubens, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; iTeos Therapeutics; Sanofi; Summit; and Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.

Faculty/Planner
Elizabeth S. Waxman, BSN, MSN, APN-BC
Adult Nurse Practitioner
The University of Texas MD Anderson Cancer Center
Department of Thoracic/Head & Neck Medical Oncology
Houston, Texas

Elizabeth S. Waxman, BSN, MSN, APN-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.5 points: Oncology Nursing Practice, Professional Practice/Performance, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 27, 2024; credit is no longer available.

Nurses at the Forefront of the Continuing Success Story of Immunotherapy in NSCLC: Best Practices for Guiding and Supporting Patients Through Treatment and Survivorship

Media: Enduring Material
Activity Release Date: April 28, 2023
Activity Expiration Date: May 27, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity based on a live MasterClass and Nursing Practice Forum, leading experts present concise learning modules combined with workshop-style demonstrations and case-based discussions to provide a practical framework for oncology nurses to facilitate optimal clinical integration of immunotherapies in advanced/metastatic and early-stage NSCLC, offering strategies to educate patients about this therapeutic class, mitigate acute and chronic immune-related adverse events (irAEs), and support patients through treatment and survivorship to help them achieve the best possible quality of life and outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms of action, safety and efficacy, and current and emerging roles of immune checkpoint inhibitors (ICIs) and combinations in advanced- and early-stage NSCLC
• Collaborate with the interprofessional team to safely and effectively integrate ICI-based regimens into individualized treatment plans for eligible patients with advanced- and early-stage NSCLC
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers about ICI-based treatment options, importance of being vigilant about irAEs, and how to overcome challenges and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Marianne Davies, DNP, ACNP, AOCNP, FAAN
Associate Professor
Yale School of Nursing
Oncology Nurse Practitioner
Yale Comprehensive Cancer Center & Smilow Cancer Center
New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Matthew A. Gubens, MD, MS
Associate Clinical Professor of Medicine
Medical Director, Thoracic Medical Oncology
Division of Hematology/Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Matthew A. Gubens, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; iTeos Therapeutics; Sanofi; Summit; and Surface.
Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.

Faculty/Planner
Elizabeth S. Waxman, BSN, MSN, APN-BC
Adult Nurse Practitioner
The University of Texas MD Anderson Cancer Center
Department of Thoracic/Head & Neck Medical Oncology
Houston, Texas

Elizabeth S. Waxman, BSN, MSN, APN-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Bristol Myers Squibb, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.5 points: Oncology Nursing Practice, Professional Practice/Performance, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 25, 2024; credit is no longer available.

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes

Activity Description

The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.

Target Audience

This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
• Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
• Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California

Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

Ian Neel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Centene Corporation/Health Net Pharmacy and Therapeutics Committee.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application

Psychologists

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/APA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 25, 2024; credit is no longer available.

Facilitating Cognitive Assessment in Primary Care for the Timely Detection of Alzheimer’s Disease: Leveraging Medicare Reimbursement Mechanisms to Improve Clinical Care

Media: Enduring Material
Activity Release Date: April 26, 2023
Activity Expiration Date: May 25, 2024
Time to Complete Activity: 60 minutes

Activity Description

The timely detection and diagnosis of Alzheimer’s disease (AD) can provide patients with numerous opportunities—earlier treatment initiation, increased eligibility for clinical trials, participation in long-term care planning, and the chance to make lifestyle changes to slow cognitive decline. In this activity, based on a recent live symposium, experts discuss practical strategies for integrating cognitive screening into routine care visits and conducting more detailed cognitive evaluations that results in a written care plan with patients who fail a brief cognitive screening assessment. Experts also share guidance on working with Medicare reimbursement mechanisms to facilitate consistent and effective use of early detection tools and practical skills to counsel patients and their caregivers before, during, and after the diagnostic process.

Target Audience

This activity has been designed to meet the educational needs of internal medicine physicians, family medicine physicians, geriatricians, advanced practice clinicians, nurses, pharmacists, psychologists, and other clinicians involved in the assessment and care of patients with or at risk for Alzheimer's disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Integrate routine cognitive assessment in outpatient visits of older adults who present with signs and symptoms of cognitive impairment to facilitate the timely diagnosis of MCI and mild dementia due to AD
• Employ appropriate tools for documentation and coding of procedures (eg, cognitive assessments) and services for patients presenting with cognitive symptoms or concerns
• Implement effective communication strategies to educate patients and caregivers about the clinical significance and prognostic implications of their cognitive assessment results

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Anna Chodos, MD, MPH
Associate Professor of Medicine
Division of Geriatrics and Division of General Internal Medicine
Zuckerberg San Francisco General Hospital
Department of Medicine
University of California
San Francisco, California

Anna Chodos, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
Ian Neel, MD
Associate Clinical Professor of Medicine
Medical Director, Geriatric Medicine Consult Service
Senior Behavioral Health
UC San Diego Medical Center
San Diego, California

Ian Neel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Centene Corporation/Health Net Pharmacy and Therapeutics Committee.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-022-H01-P
Type of Activity: Application

Psychologists

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/APA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 17, 2024; credit is no longer available.

Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

Activity Description and Educational Objectives

Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care.

Upon completion of this activity, participants should be better able to:

• Describe the pathophysiology and potential therapeutic targets for IBS-C
• Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management
• Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Target Audience

This activity has been designed to meet the educational needs of gastroenterology nurses and other healthcare professionals involved in the care of patients with irritable bowel syndrome with constipation (IBS-C).

Requirements for Successful Completion

Successful completion of this accredited continuing education activity is based on:

• Being registered for this activity
• Viewing the program in its entirety
• Completion of the post-test
• Completion of the evaluation

Media: Enduring Material
Release and Expiration Dates: April 18, 2023 - May 17, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Per the disclosure policy of the Society of Gastroenterology Nurses and Associates, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any ineligible companies related to this activity. These relationships are mitigated and materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Co-Chairs & Presenters
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speaker for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Kimberly Kearns, APRN, ANP-BC
DULY Gastroenterology Department
DULY Health and Care
Hoffman Estates, Illinois

Kimberly Kearns, APRN, ANP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ardelyx; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer; and Salix Pharmaceuticals.
Speakers Bureau participant with Janssen Pharmaceuticals, Inc.; Lilly; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Society of Gastroenterology Nurses and Associates (SGNA) staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The Society of Gastroenterology Nurses and Associates, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Upon successful completion of this accredited continuing education activity, participants will be awarded 1.0 contact hours.

Support

This activity is supported by an educational grant from Ardelyx.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, and Society of Gastroenterology Nurses and Associates (SGNA) are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Society of Gastroenterology Nurses and Associates (SGNA). The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 17, 2024; credit is no longer available.

Addressing Unmet Nursing Needs in the Management of IBS-C: Understanding the Mechanism of Disease, Newer Therapies, and Coordinated Approaches to Treatment Barriers

Activity Description and Educational Objectives

Patients with irritable bowel syndrome with constipation (IBS-C) are often more comfortable discussing their concerns with the nurses on their healthcare team, which demonstrates the need for team-based care in order to maximize management, enhance outcomes, and improve quality of life. This activity features an expert overview of the pathophysiology of IBS-C and targets for therapy, including novel NHE3 inhibitors, as well as evidence-based treatment approaches with a focus on identifying and overcoming barriers to guideline-based care. Hear about recent advances in the diagnosis and treatment of IBS-C, specifically the mechanisms of the condition, current and emerging therapies, and coordinated approaches for overcoming barriers to care.

Upon completion of this activity, participants should be better able to:

• Describe the pathophysiology and potential therapeutic targets for IBS-C
• Use patient-centered tactics and tools to overcome barriers to guideline-directed IBS-C management
• Create team-based approaches to IBS-C management in accordance with current evidence and guidelines, recognizing the appropriate use of current and emerging therapeutic agents

Target Audience

This activity has been designed to meet the educational needs of gastroenterology nurses and other healthcare professionals involved in the care of patients with irritable bowel syndrome with constipation (IBS-C).

Requirements for Successful Completion

Successful completion of this accredited continuing education activity is based on:

• Being registered for this activity
• Viewing the program in its entirety
• Completion of the post-test
• Completion of the evaluation

Media: Enduring Material
Release and Expiration Dates: April 18, 2023 - May 17, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

Per the disclosure policy of the Society of Gastroenterology Nurses and Associates, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any ineligible companies related to this activity. These relationships are mitigated and materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Co-Chairs & Presenters
Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF
Dan and Lillie Sterling Professor of Medicine
McGovern Medical School
Chief, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, FACP, FACG, FASGE, AGAF, RFF, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Speaker for AbbVie Inc.; Ardelyx; QOL Medical, LLC; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Kimberly Kearns, APRN, ANP-BC
DULY Gastroenterology Department
DULY Health and Care
Hoffman Estates, Illinois

Kimberly Kearns, APRN, ANP-BC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Ardelyx; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer; and Salix Pharmaceuticals.
Speakers Bureau participant with Janssen Pharmaceuticals, Inc.; Lilly; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Society of Gastroenterology Nurses and Associates (SGNA) staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships. All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

The Society of Gastroenterology Nurses and Associates, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Upon successful completion of this accredited continuing education activity, participants will be awarded 1.0 contact hours.

Support

This activity is supported by an educational grant from Ardelyx.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This NCPD Activity

PVI, PeerView Institute for Medical Education, and Society of Gastroenterology Nurses and Associates (SGNA) are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Society of Gastroenterology Nurses and Associates (SGNA). The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 29, 2024; credit is no longer available.

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
• Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
• Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 29, 2024; credit is no longer available.

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

Media: Enduring Material
Activity Release Date: March 31, 2023
Activity Expiration Date: April 29, 2024
Time to Complete Activity: 60 minutes

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
• Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
• Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 15, 2024; credit is no longer available.

Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

Media: Enduring Material
Activity Release Date: March 2, 2023
Activity Expiration Date: April 15, 2024
Time to Complete Activity: 60 minutes

Activity Description

Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA).

In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals involved in the interdisciplinary and interprofessional diagnosis and care of patients with or at risk for Alzheimer’s disease (AD), including neurologists, psychiatrists, geneticists, family and internal medicine physicians, advanced practice clinicians, psychologists, pharmacists, social workers, and genetic counselors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care
• Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting
• Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert C. Green, MD, MPH
Professor of Medicine (Genetics)
Mass General Brigham
Harvard Medical School
Boston, Massachusetts

Robert C. Green, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AIA; Allelica, Inc.; Atria; Fabric; Genome Web; Genomic Life; GRAIL, Inc.; Verily Life Sciences LLC; and VinBigData.
Other Financial or Material Support as Co-Founder of Genome Medical and Nurture Genomics.

Faculty/Planner
Liana G. Apostolova, MS, MD, FAAN
Distinguished Professor in Neurology
Barbara and Peer Baekgaard Chair in Alzheimer’s Disease Research
Professor of Radiology and Medical and Molecular Genetics
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

Liana G. Apostolova, MS, MD, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Florida Department of Health; Food and Drug Administration (FDA); GE Healthcare; Genentech, Inc.; IQVIA Inc.; Lilly; New Mexico Exploratory ADRC; TwoLabs, LLC; and UAB Nathan Schock Center.
Grant/Research Support from AVID Pharmaceuticals; F. Hoffmann-La Roche Ltd; Life Molecular Imaging; and Lilly.

Faculty/Planner
Stephen P. Salloway, MD, MS
Martin M. Zucker Professor of Psychiatry and Human Behavior
Professor of Neurology
Alpert Medical School of Brown University
Associate Director
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

Stephen P. Salloway, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acumen Pharmaceuticals, Inc.; Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Lilly; Novo Nordisk Inc.; and Prothena Corporation plc.
Grant/Research Support from Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-017-H01-P
Type of Activity: Application

Social Workers

As a Jointly Accredited Organization, PVI, PeerView Institute for Medical Education, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 general continuing education credits.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/ASWB-ACE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on April 15, 2024; credit is no longer available.

Revisiting the Role of Genetic Testing in Patients at Risk for Late-Onset Alzheimer’s Disease: How Will the Latest Evidence and Evolving Management Paradigm Impact Treatment Decisions for Your Patients?

Media: Enduring Material
Activity Release Date: March 2, 2023
Activity Expiration Date: April 15, 2024
Time to Complete Activity: 60 minutes

Activity Description

Late-onset Alzheimer’s disease (LOAD) has a substantial genetic component, with heritability estimated to be between 40% and 80%, and the APOE ε4 allele is the strongest individual genetic risk factor for LOAD. Until recently, the APOE genotype test has been primarily used as a research tool and not recommended for clinical use. However, with the recent advances in disease-modifying therapies (DMTs), including several anti–amyloid monoclonal antibodies approved or in late-stage development, it is more important to determine which patients have the APOE ε4 allele and whether these patients are at an elevated risk of developing amyloid-related imaging abnormalities (ARIA).

In this activity, based on a recent live webcast, experts examine the significance of APOE ε4 carrier status on the risk for developing LOAD, as well as the potential implications for patient care, including the increased risk for ARIA in patients taking anti-amyloid monoclonal antibodies. They provide guidance on identifying patients who may be candidates for genetic risk testing and share their best practices for interpreting and disclosing APOE test results and providing appropriate genetic counseling to patients and their families.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals involved in the interdisciplinary and interprofessional diagnosis and care of patients with or at risk for Alzheimer’s disease (AD), including neurologists, psychiatrists, geneticists, family and internal medicine physicians, advanced practice clinicians, psychologists, pharmacists, social workers, and genetic counselors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the significance of APOE ε4 carrier status on the risk for late-onset Alzheimer's disease (LOAD) and the potential implications for patient care
• Identify patients who may be candidates for genetic risk testing, and provide guidance on the benefits and limitations of direct-to-consumer testing versus genetic testing that is performed in a healthcare setting
• Interpret and share genetic risk test results with patients and their families in a clear, understandable manner, and tailor genetic counseling services to individual patients’ needs in consultation with other members of the healthcare team

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert C. Green, MD, MPH
Professor of Medicine (Genetics)
Mass General Brigham
Harvard Medical School
Boston, Massachusetts

Robert C. Green, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AIA; Allelica, Inc.; Atria; Fabric; Genome Web; Genomic Life; GRAIL, Inc.; Verily Life Sciences LLC; and VinBigData.
Other Financial or Material Support as Co-Founder of Genome Medical and Nurture Genomics.

Faculty/Planner
Liana G. Apostolova, MS, MD, FAAN
Distinguished Professor in Neurology
Barbara and Peer Baekgaard Chair in Alzheimer’s Disease Research
Professor of Radiology and Medical and Molecular Genetics
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

Liana G. Apostolova, MS, MD, FAAN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Florida Department of Health; Food and Drug Administration (FDA); GE Healthcare; Genentech, Inc.; IQVIA Inc.; Lilly; New Mexico Exploratory ADRC; TwoLabs, LLC; and UAB Nathan Schock Center.
Grant/Research Support from AVID Pharmaceuticals; F. Hoffmann-La Roche Ltd; Life Molecular Imaging; and Lilly.

Faculty/Planner
Stephen P. Salloway, MD, MS
Martin M. Zucker Professor of Psychiatry and Human Behavior
Professor of Neurology
Alpert Medical School of Brown University
Associate Director
Brown Center for Alzheimer’s Disease Research
Providence, Rhode Island

Stephen P. Salloway, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Acumen Pharmaceuticals, Inc.; Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Lilly; Novo Nordisk Inc.; and Prothena Corporation plc.
Grant/Research Support from Biogen; Eisai Co., Ltd; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-017-H01-P
Type of Activity: Application

Social Workers

As a Jointly Accredited Organization, PVI, PeerView Institute for Medical Education, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1 general continuing education credits.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE/ASWB-ACE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on February 20, 2024; credit is no longer available.

What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice

Media: Enduring Material
Activity Release Date: February 21, 2023
Activity Expiration Date: February 20, 2024
Time to Complete Activity: 30 minutes

Activity Description

Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life.

Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising.

This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, specialty NPs and PAs, and other healthcare professionals involved in the care of patients with EoE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease
• Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team
• Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Evan S. Dellon, MD, MPH
Professor of Medicine and Adjunct Professor of Epidemiology
Director, UNC Center for Esophageal Diseases and Swallowing (CEDAS)
Division of Gastroenterology and Hepatology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Evan S. Dellon, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AbbVie Inc.; Adare Pharma Solutions/Ellodi Pharmaceuticals; Aimmune Therapeutics; Akesa Pharma Pty Ltd; Alfasigma S.p.A.; ALK; Allakos Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN; AstraZeneca; Avir Pharma; Biorasi, LLC; Calypso Biotech; Celgene Corporation/Receptos/Bristol Myers Squibb; Celldex Therapeutics; EsoCap AG; Eupraxia Pharmaceuticals; Ferring B.V.; GSK; Gossamer Bio; Holoclara; Invea Therapeutics, Inc.; Landos Biopharma, Inc.; Lilly; Lucid Diagnostics; Morphic Therapeutic, Inc.; Nexstone Immunology; Nutricia; Parexel International Corporation/Calyx Chemicals & Pharmaceuticals Ltd.; Phathom Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; Robarts/Alimentiv (US) Inc.; Salix Pharmaceuticals; Sanofi; Shire/Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; and Upstream Bio, Inc.
Grant/Research Support from Adare Pharma Solutions/Ellodi Pharmaceuticals; Allakos Inc.; Arena Pharmaceuticals; AstraZeneca; Celgene Corporation/Receptos/Bristol Myers Squibb; GSK; Meritage Pharma, Inc.; Miraca; Nutricia; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; and Shire/Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on February 20, 2024; credit is no longer available.

What's New in the Management of Eosinophilic Esophagitis: Working Together to Integrate Targeted Treatment Options Into Practice

Media: Enduring Material
Activity Release Date: February 21, 2023
Activity Expiration Date: February 20, 2024
Time to Complete Activity: 30 minutes

Activity Description

Eosinophilic esophagitis (EoE) is a chronic allergic type 2 inflammatory disease characterized by a clinical and pathologic phenotype of progressive esophageal dysfunction due to tissue inflammation and fibrosis. Diagnosis of EoE is frequently missed or delayed, which can lead to such complications as esophageal stricture and reduced patient quality of life.

Fortunately, targeted biologic therapies already approved for other type 2 inflammatory disorders are approved, or are in development, for the treatment of EoE and appear promising.

This case-based activity will offer expert insights for recognizing and diagnosing EoE, monitoring and managing EoE, and integrating targeted therapies into practice.

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, specialty NPs and PAs, and other healthcare professionals involved in the care of patients with EoE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Diagnose eosinophilic esophagitis (EoE) promptly according to the latest guidelines and criteria to decrease the risk of complications precipitated by uncontrolled disease
• Apply the latest clinical research developments and updates in treatment guidelines to the management of EoE in collaboration with the healthcare team
• Select treatment, including novel targeted biologic therapies, for patients with EoE based on the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Evan S. Dellon, MD, MPH
Professor of Medicine and Adjunct Professor of Epidemiology
Director, UNC Center for Esophageal Diseases and Swallowing (CEDAS)
Division of Gastroenterology and Hepatology
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Evan S. Dellon, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Abbott; AbbVie Inc.; Adare Pharma Solutions/Ellodi Pharmaceuticals; Aimmune Therapeutics; Akesa Pharma Pty Ltd; Alfasigma S.p.A.; ALK; Allakos Inc.; Amgen Inc.; Arena Pharmaceuticals; ASLAN; AstraZeneca; Avir Pharma; Biorasi, LLC; Calypso Biotech; Celgene Corporation/Receptos/Bristol Myers Squibb; Celldex Therapeutics; EsoCap AG; Eupraxia Pharmaceuticals; Ferring B.V.; GSK; Gossamer Bio; Holoclara; Invea Therapeutics, Inc.; Landos Biopharma, Inc.; Lilly; Lucid Diagnostics; Morphic Therapeutic, Inc.; Nexstone Immunology; Nutricia; Parexel International Corporation/Calyx Chemicals & Pharmaceuticals Ltd.; Phathom Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; Robarts/Alimentiv (US) Inc.; Salix Pharmaceuticals; Sanofi; Shire/Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; and Upstream Bio, Inc.
Grant/Research Support from Adare Pharma Solutions/Ellodi Pharmaceuticals; Allakos Inc.; Arena Pharmaceuticals; AstraZeneca; Celgene Corporation/Receptos/Bristol Myers Squibb; GSK; Meritage Pharma, Inc.; Miraca; Nutricia; Regeneron Pharmaceuticals Inc.; Revolo Biotherapeutics; and Shire/Takeda Pharmaceuticals U.S.A., Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on January 30, 2024; credit is no longer available.

Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management

Media: Enduring Material
Activity Release Date: January 31, 2023
Activity Expiration Date: January 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematology-oncology nurses, pharmacists, cardiologists, and other clinicians involved in the care of patients with B-cell malignancies.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues
• Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection
• Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Christina Russomanno, RN, MS, NP-C
Nurse Practitioner, Leukemia Service
Director of Nursing, Outpatient Hematology/Oncology
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Christina Russomanno, RN, MS, NP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-010-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on January 30, 2024; credit is no longer available.

Building a Safety-Centric Culture in B-Cell Cancers: Interprofessional Insights on Optimizing BTKi Efficacy Through Safety Management

Media: Enduring Material
Activity Release Date: January 31, 2023
Activity Expiration Date: January 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activity, a panel of hematology-oncology experts utilize short lectures and case-based discussions to illustrate how the interprofessional, multidisciplinary team can use safety considerations to select therapy, manage unique and challenging AEs, educate and counsel patients, and ensure vastly improved outcomes for patients with CLL, MCL, and other B-cell cancers.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematology-oncology nurses, pharmacists, cardiologists, and other clinicians involved in the care of patients with B-cell malignancies.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize current safety considerations with first- and second-generation BTK inhibitors, including mechanistic aspects that affect toxicity, head-to-safety data, and general class-wide AE issues
• Manage and mitigate toxicity associated with BTK inhibitors, including through active interventions and judicious treatment selection
• Develop team strategies for safety management that include multidisciplinary collaboration, safety-informed treatment selection, and outreach to patients with B-cell cancers receiving BTK inhibitor therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Faculty/Planner
Christina Russomanno, RN, MS, NP-C
Nurse Practitioner, Leukemia Service
Director of Nursing, Outpatient Hematology/Oncology
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Christina Russomanno, RN, MS, NP-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-010-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on December 19, 2023; credit is no longer available.

Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care

Activity Description and Educational Objectives

Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options.

Upon completion of this activity, participants should be better able to:

• Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis
• Identify patients with psoriasis who are most likely to benefit from novel oral treatments
• Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines
• Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis

Target Audience

This activity has been designed to meet the educational needs of advanced practice clinicians (NPs/PAs), physicians, and other healthcare professionals that provide care to patients with psoriasis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 20, 2022 - December 19, 2023
Time to Complete: 30 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.

Presenter
Douglas DiRuggiero, DMSc, MHS, PA-C
Rome Dermatology Center
Rome, Georgia

Douglas DiRuggiero, DMSc, MHS, PA-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Lilly; Novartis Pharmaceuticals Corporation; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Amgen Inc.; Lilly; Novartis Pharmaceuticals Corporation; and UCB, Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6902-22-T.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on December 19, 2023; credit is no longer available.

Taking a Team-Based Approach to Moderate to Severe Psoriasis in an Era of Expanding Oral Treatment Options: Advanced Practice Clinicians as Key Partners in Care

Activity Description and Educational Objectives

Psoriasis is a widely prevalent, chronic, systemic, immune-mediated disease that substantially impairs patients’ physical health, quality of life and work productivity. Nearly one-quarter of people with psoriasis have cases that are considered moderate to severe. Despite the availability of effective systemic therapy, many patients remain undertreated or even untreated and are dissatisfied with current treatments. In this activity, two experts review the rationale for TYK2 inhibition as a novel approach for the treatment of moderate to severe psoriasis. In addition, key information for the first-in-class, oral, selective TYK2 inhibitor will be provided, as well as the key roles that advanced practice clinicians (eg, NPs, PAs) play in the management of patients with psoriasis in an era of expanding oral treatment options.

Upon completion of this activity, participants should be better able to:

• Describe the rationale for targeting the TYK2 kinase as it relates to novel approaches for the treatment of moderate to severe psoriasis
• Identify patients with psoriasis who are most likely to benefit from novel oral treatments
• Select among established and novel therapies to personalize management plans for patients with psoriasis based on efficacy and safety evidence and guidelines
• Facilitate care coordination and communication with patients and other healthcare team members that fosters a whole patient approach to managing psoriasis

Target Audience

This activity has been designed to meet the educational needs of advanced practice clinicians (NPs/PAs), physicians, and other healthcare professionals that provide care to patients with psoriasis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: December 20, 2022 - December 19, 2023
Time to Complete: 30 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP
VA Portland Health Care System
Dermatology Service
NP Residency Director
Portland, Oregon

Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Arcutis Biotherapeutics, Inc.; Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; LEO Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; Sun Pharmaceutical Industries Limited; and UCB, Inc.

Presenter
Douglas DiRuggiero, DMSc, MHS, PA-C
Rome Dermatology Center
Rome, Georgia

Douglas DiRuggiero, DMSc, MHS, PA-C, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Lilly; Novartis Pharmaceuticals Corporation; and UCB, Inc.
Speakers Bureau participant with AbbVie Inc.; Amgen Inc.; Lilly; Novartis Pharmaceuticals Corporation; and UCB, Inc.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6902-22-T.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView